about
Recurring mutations found by sequencing an acute myeloid leukemia genomeVery late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myelomaCXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activityA pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myelomaSmall Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenesThe characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomesPrevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma
P50
Q24634204-15215036-79C2-463B-A03A-DAC95472FF2DQ27316139-3F11FC04-3D03-4710-B232-A46132238B5FQ28587353-299D3877-9723-4328-973F-48BE013DCE4BQ33716570-018B37B6-FB54-483D-AA51-C9A230786ED2Q33845985-1170F7DA-AFDE-45E1-9441-A46AEE6EC5F5Q35590573-15CA9A02-9A96-4C76-9A69-F470F39C1E29Q35641644-2EFD2769-FA82-46D4-B596-6DB5C8FADCFCQ35644558-0C2B1682-31E2-4625-B863-1EB41618EABEQ35804404-C732D5F3-8BD7-472E-B71E-164164427DF2Q36508949-90E1F3A0-1013-482A-8DFE-8BFA13504E06Q37633986-BD9867FB-AFB5-4EDC-A53C-73AE205DA88AQ38718452-355C76E9-6C99-41AD-99B3-B594B8025ACAQ39895963-9DE6BCC9-5807-4F45-962F-3B50268AEE60Q40406189-06477C30-C831-435C-9422-B02EF3D8894CQ40766981-42B45E9A-DE00-4FB5-9825-A5B13C467915Q41222600-365A4963-DF9B-4374-B829-0443DFECE89BQ41942186-6AF17B45-F1F9-413E-A643-44873D77FCB3Q44814428-D5825CF7-CACA-4BD9-9C69-DE7D28652252Q49777578-4FE0F19A-15EC-472E-83B2-C72E2E83B2AEQ57720872-51A607D6-0C09-45D8-B57C-B07AEE066B8FQ59798935-70AA89B0-F92B-40CD-9C3F-A14ADE91A4EC
P50
description
researcher ORCID ID = 0000-0003-4518-7123
@en
wetenschapper
@nl
name
Michael H Tomasson
@ast
Michael H Tomasson
@en
Michael H Tomasson
@es
Michael H Tomasson
@nl
type
label
Michael H Tomasson
@ast
Michael H Tomasson
@en
Michael H Tomasson
@es
Michael H Tomasson
@nl
prefLabel
Michael H Tomasson
@ast
Michael H Tomasson
@en
Michael H Tomasson
@es
Michael H Tomasson
@nl
P1153
6601996854
P31
P496
0000-0003-4518-7123